NCT07370766Recruiting
Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
A Real-world, Longitudinal Observational Study of the Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
Source: ClinicalTrials.gov · Last updated 11 Sept 2026
Brief summary (registry, in English)
This is a multi-centre, non-interventional, open-label, prospective observational study that will be conducted across Canada over 52-week duration. Approximately 80 patients who are initiating tildrakizumab as part of their routine care through the ILUMYA SUPPORT® Program and meet the study's eligibility criteria will be enrolled. Specifically, the study will enroll patients with Fitzpatrick scale skin types III and above. The real-world impact, safety and effectiveness of tildrakizumab on patients with moderate-to-severe plaque psoriasis (PsO) remain largely undocumented in Canada, despite its approval in 2018. Given Canada's diverse population, this study presents an opportunity to evaluate tildrakizumab's quality of life, safety and effectiveness in specific demographic groups, particularly those patients with Fitzpatrick scale skin type III and above. The findings from this study will help optimize care, address unmet needs, and ensure that treatment outcomes are inclusive and reflective of Canada's diverse population.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 80 (estimated)
- First submitted
- 12 Jan 2026
- Start date
- 25 Nov 2025
- Primary completion date
- 30 May 2027
- Lead sponsor
- Chronicle Academy
- Diseases
- Psoriasis
- NCT number
- NCT07370766
What you commit to
- Study type: Observational
- Planned participants: 80
- From 25 Nov 2025 to the primary completion date, 30 May 2027
- 7 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrently taking any oral medication for treatment of PsO (e.g. methotrexate, cyclosporin, acitretin)
- Concurrent medical condition or significant comorbidities that, in the investigator's opinion, would prevent participation in the study or interfere with study assessments
- Prior (within 30 days) or actively participating in other interventional clinical trial(s).
Other illness
- Known hypersensitivity to tildrakizumab, its excipients, or components of the container, as outlined in the Product Monograph.
- Any other condition that, in the opinion of the investigator, could create a hazard to the participant's safety, endanger the study procedures, or interfere with the interpretation of study results
Other
- Diagnosis of only palmoplantar psoriasis
- Women of childbearing potential who are pregnant, planning to become pregnant, or breastfeeding.
- Unable or unwilling to comply with study procedures including completing questionnaire.
Who the study is looking for
- Adults aged 18 years or older.
- Diagnosis of moderate-to-severe chronic plaque-type PsO with Fitzpatrick scale type III or above (BSA \>/=3%).
- Candidate for phototherapy and/or systemic therapy.
- Planning to initiate tildrakizumab as part of routine clinical care through the ILUMYA SUPPORT® Program for the treatment of plaque PsO but has not yet received their first dose.
- Decision to treat with tildrakizumab must be made independently of and prior to study recruitment.
- Must be able to read, understand, and communicate in English.
- Must be willing to participate in the study and capable to provide informed consent
- Able to comply with all study procedures and attend all study visits
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Benchmark Dermatology Coordinator of this site? Confirm its status | Burlington | Canada | Recruiting |
| Locke Dermatology Coordinator of this site? Confirm its status | Hamilton | Canada | Recruiting |
| Panorama Dermatology Clinic Coordinator of this site? Confirm its status | Kanata | Canada | Recruiting |
| Vital Medical Centre Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
| Factor Dermatology Coordinator of this site? Confirm its status | Ottawa | Canada | Recruiting |
| Elevate Dermatology Coordinator of this site? Confirm its status | Pickering | Canada | Recruiting |
| Saskatoon Dermatology Centre Coordinator of this site? Confirm its status | Saskatoon | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.